NovaBridge Biosciences Debt Securities, Available-for-sale, Unrealized Gain (Loss)
NovaBridge Biosciences (NBP) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $11.58 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-04-07
- NovaBridge Biosciences debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $2.08M.
- NovaBridge Biosciences debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $5.85M.
- NovaBridge Biosciences debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-12-31 was -$8.52M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.08M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $7.94M derived: sum of 2 quarters · filed 2026-04-07 | $11.58M 20-F · filed 2026-04-07 | |
| 2025-09-30 | $5.85M derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $9.50M 6-K · filed 2025-12-18 | ||
| 2025-06-30 | $3.64M 6-K · filed 2025-10-06 | |||
| 2024-12-31 | -$8.52M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | -$8.17M 20-F · filed 2026-04-07 | ||
| 2024-09-30 | $350.00K 6-K · filed 2025-12-18 |